TrialReader


The Safety & Efficacy of Terlipressin vs Octreotide for the Control of Variceal Bleed

NCT00534677 — Phase 4, Completed, 320 participants, Aga Khan University

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

Efficacy And Safety Of Terlipressin Vs Octreotide As Adjuvant Therapy In Bleeding Esophageal Varices

RegistryNCT00534677
StatusCompleted
PhasePhase 4
Study typeInterventional; randomized, parallel, masking: triple, treatment
Enrollment320 (Actual)
SponsorAga Khan University (Other)
ConditionsPortal Hypertension, Cirrhosis, Hematemesis, Melena
InterventionsTerlipressin, Octreotide (Drug)
Datesstart 2004-05-01, completion 2005-07-01, first posted 2007-09-26, last updated 2007-12-05
Locations1 site in Pakistan

Related Papers Related Patents Related Grants Related Experts
AI Assistant Save
All trials for Portal Hypertension All trials for Cirrhosis All trials of Terlipressin All trials of Octreotide

-Summary

Terlipressin and Octreotide are two common agents used as adjuvants in the management of variceal bleeding. Both agents have been claimed equivalent to endoscopic therapy in randomized studies. There are no head to head clinical trials of these two agents available in the literature. We aimed to compare the efficacy and safety of Terlipressin and Octreotide in combination with Endoscopic Variceal band Ligation (EVL)in patients presenting with Esophageal Variceal Bleed (EVB).

Expand all sections  ·  Collapse all

+Detailed description

The effectiveness of combining Endoscopic treatment with Octreotide or Terlipressin has not been prospectively studied in esophageal variceal hemorrhage (EVH).

This prospective, randomized clinical trial will help us in better patient management more efficiently and cost effectively.

+Arms and interventions

ArmTypeInterventionsDescription
AActive comparatorDrug: Terlipressin
BActive comparatorDrug: Octreotide
  • Terlipressin (Drug), also known as Novapresin: 2 mg stat \& then 1 mg q6h iv and Placebo of Octreotide
  • Octreotide (Drug), also known as sandostatin: Octreotide 50mcg/hr infusion \& a placebo of Terlipressin

+Outcome measures

Primary outcomes

  • Safety & Efficacy [5 days]

+Eligibility

Sex: All, ages: 18 Years to any

Inclusion Criteria:

* All cirrhotic patients with upper GI bleed secondary to esophageal varices of 18 years or more of age

Exclusion Criteria:

* Ulcerative esophagitis,
* Mallory Weiss tear,
* Bleeding gastric or duodenal ulcers,
* Bleeding from gastric varices or portal hypertensive gastropathy and
* Upper GI bleed as a result of thrombocytopenia or bleeding diathesis.

+Locations (1)

FacilityCityCountryStatus
The Aga Khan University HospitalKarachi, SindhPakistan

+Investigators

My Notes